Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALB | P02768 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | TYMP | P19971 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13664000 | 0.76 | SLC28A1 (0.48) | — | |
| SCHEMBL13667652 | 0.75 | ALDH1A1 (0.47) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL12280514 | 0.75 | ALDH1A1 (0.47) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL8660778 | 0.73 | TK1 (0.50) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL9149865 | 0.73 | TK1 (0.50) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL13664020 | 0.73 | ALDH1A1 (0.45) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL14544398 | 0.73 | ALDH1A1 (0.45) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL9310153 | 0.72 | TK1 (0.60) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL30807817 | 0.72 | ALDH1A1 (0.53) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL14124039 | 0.72 | TK1 (0.50) | TK1ALDH1A1LMNAALBPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270431-A1 | Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2007047793-A2 | CYCLOPENTENOL NUCLEOSIDE COMPOUNDS, INTERMEDIATES FOR THEIR SYNTHESIS AND METHODS OF TREATING VIRAL INFECTIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270431-A1 | Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections | REV1, NSUN2, ORC3 | TK1 501/4885ALDH1A1 1749/4885LMNA 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.